These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16247347)

  • 1. PPAR-gamma-agonists' renal effects.
    Izzedine H; Launay-Vacher V; Buhaescu I; Heurtier A; Baumelou A; Deray G
    Minerva Urol Nefrol; 2005 Dec; 57(4):247-60. PubMed ID: 16247347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.
    Ma LJ; Marcantoni C; Linton MF; Fazio S; Fogo AB
    Kidney Int; 2001 May; 59(5):1899-910. PubMed ID: 11318962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.
    Sarafidis PA; Bakris GL
    Kidney Int; 2006 Oct; 70(7):1223-33. PubMed ID: 16883325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist inhibits transforming growth factor-beta1 and matrix production in human dermal fibroblasts.
    Zhang GY; Cheng T; Zheng MH; Yi CG; Pan H; Li ZJ; Chen XL; Yu Q; Jiang LF; Zhou FY; Li XY; Yang JQ; Chu TG; Gao WY
    J Plast Reconstr Aesthet Surg; 2010 Jul; 63(7):1209-16. PubMed ID: 19617014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of vascular relaxation, lipolysis and glucose uptake by peroxisome proliferator-activated receptor-gamma activation in +db/+m and +db/+db mice.
    Seto SW; Lam TY; Leung GP; Au AL; Ngai SM; Chan SW; Kwan YW
    Eur J Pharmacol; 2007 Oct; 572(1):40-8. PubMed ID: 17603034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Troglitazone suppresses transforming growth factor-beta1-induced collagen type I expression in keloid fibroblasts.
    Zhang GY; Yi CG; Li X; Ma B; Li ZJ; Chen XL; Guo SZ; Gao WY
    Br J Dermatol; 2009 Apr; 160(4):762-70. PubMed ID: 19120328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
    Calkin AC; Giunti S; Jandeleit-Dahm KA; Allen TJ; Cooper ME; Thomas MC
    Nephrol Dial Transplant; 2006 Sep; 21(9):2399-405. PubMed ID: 16720596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiazolidinediones--tools for the research of metabolic syndrome X.
    Komers R; Vrána A
    Physiol Res; 1998; 47(4):215-25. PubMed ID: 9803467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Troglitazone inhibits synthesis of transforming growth factor-beta1 and reduces matrix production in human peritoneal mesothelial cells.
    Peng Y; Liu H; Liu F; Liu Y; Li J; Chen X
    Nephrology (Carlton); 2006 Dec; 11(6):516-23. PubMed ID: 17199790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPARgamma agonists: killing two birds with one stone?
    Ritz E
    J Hypertens; 2004 Sep; 22(9):1673-4. PubMed ID: 15311092
    [No Abstract]   [Full Text] [Related]  

  • 11. PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance.
    Gaikwad AB; Viswanad B; Ramarao P
    Pharmacol Res; 2007 May; 55(5):400-7. PubMed ID: 17369046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of peroxisome proliferator activated receptor-gamma (PPAR gamma) ligands in proximal tubular cells: thiazolidinediones are partial PPAR gamma agonists.
    Chana RS; Lewington AJ; Brunskill NJ
    Kidney Int; 2004 Jun; 65(6):2081-90. PubMed ID: 15149321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
    Panunti B; Fonseca V
    Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
    Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
    Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats.
    Bilan VP; Salah EM; Bastacky S; Jones HB; Mayers RM; Zinker B; Poucher SM; Tofovic SP
    J Endocrinol; 2011 Sep; 210(3):293-308. PubMed ID: 21680617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis.
    Milam JE; Keshamouni VG; Phan SH; Hu B; Gangireddy SR; Hogaboam CM; Standiford TJ; Thannickal VJ; Reddy RC
    Am J Physiol Lung Cell Mol Physiol; 2008 May; 294(5):L891-901. PubMed ID: 18162602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity.
    Patel JJ; Butters OR; Arnett TR
    Cell Biochem Funct; 2014 Jun; 32(4):368-77. PubMed ID: 24615887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential modulation of COX-2 expression in A549 airway epithelial cells by structurally distinct PPAR(gamma) agonists: evidence for disparate functional effects which are independent of NF-(kappa)B and PPAR(gamma).
    Patel KM; Wright KL; Whittaker P; Chakravarty P; Watson ML; Ward SG
    Cell Signal; 2005 Sep; 17(9):1098-110. PubMed ID: 15993751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.